CORALABPharmaceuticals
Coral Laboratories Ltd — Profit & Loss Statement
₹370.55
-4.99%
Coral Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.20 Cr | -0.04 Cr | 82474.89 | 0.23 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.24 | 0.22 | 0.24 | — |
| Normalized EBITDA | 35.35 Cr | 22.87 Cr | 10.71 Cr | 13.03 Cr | — |
| Total Unusual Items | -0.77 Cr | -0.16 Cr | 0.04 Cr | 0.96 Cr | — |
| Total Unusual Items Excluding Goodwill | -0.77 Cr | -0.16 Cr | 0.04 Cr | 0.96 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Reconciled Depreciation | 2.01 Cr | 1.98 Cr | 2.18 Cr | 1.99 Cr | — |
| Reconciled Cost Of Revenue | 53.02 Cr | 37.25 Cr | 49.26 Cr | 42.64 Cr | — |
| EBITDA | 34.58 Cr | 22.71 Cr | 10.74 Cr | 13.99 Cr | — |
| EBIT | 32.57 Cr | 20.73 Cr | 8.56 Cr | 12.00 Cr | — |
| Net Interest Income | -0.10 Cr | -2000.00 | 1.45 Cr | 1.61 Cr | — |
| Interest Expense | 0.10 Cr | 2000.00 | 0.34 Cr | 0.14 Cr | — |
| Normalized Income | 24.73 Cr | 15.91 Cr | 6.42 Cr | 8.31 Cr | — |
| Net Income From Continuing And Discontinued Operation | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Total Expenses | 90.78 Cr | 69.40 Cr | 76.26 Cr | 67.00 Cr | — |
| Diluted NI Availto Com Stockholders | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Net Income Common Stockholders | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Net Income Including Noncontrolling Interests | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Net Income Continuous Operations | 24.16 Cr | 15.79 Cr | 6.45 Cr | 9.05 Cr | — |
| Tax Provision | 8.31 Cr | 4.94 Cr | 1.78 Cr | 2.81 Cr | — |
| Pretax Income | 32.47 Cr | 20.73 Cr | 8.23 Cr | 11.86 Cr | — |
| Other Non Operating Income Expenses | 9.11 Cr | 6.63 Cr | 1.87 Cr | 1.68 Cr | — |
| Special Income Charges | -0.77 Cr | -0.16 Cr | 0.04 Cr | 0.96 Cr | — |
| Net Non Operating Interest Income Expense | -0.10 Cr | -2000.00 | 1.45 Cr | 1.61 Cr | — |
| Interest Expense Non Operating | 0.10 Cr | 2000.00 | 0.34 Cr | 0.14 Cr | — |
| Operating Income | 24.23 Cr | 14.26 Cr | 1.63 Cr | 6.22 Cr | — |
| Operating Expense | 37.76 Cr | 32.15 Cr | 27.00 Cr | 24.35 Cr | — |
| Other Operating Expenses | 21.01 Cr | 18.98 Cr | 8.35 Cr | 8.22 Cr | — |
| Depreciation And Amortization In Income Statement | 2.01 Cr | 1.98 Cr | 2.18 Cr | 1.99 Cr | — |
| Depreciation Income Statement | 2.01 Cr | 1.98 Cr | 2.17 Cr | 1.98 Cr | — |
| Gross Profit | 61.99 Cr | 46.41 Cr | 28.63 Cr | 30.58 Cr | — |
| Cost Of Revenue | 53.02 Cr | 37.25 Cr | 49.26 Cr | 42.64 Cr | — |
| Total Revenue | 115.01 Cr | 83.66 Cr | 77.89 Cr | 73.22 Cr | — |
| Operating Revenue | 115.01 Cr | 83.66 Cr | 77.89 Cr | 73.22 Cr | — |
| Interest Income | — | 3.36 Cr | 1.79 Cr | 1.75 Cr | 2.04 Cr |
| Rent Expense Supplemental | — | 1.74 Cr | 2.41 Cr | 0.55 Cr | 0.38 Cr |
| Diluted Average Shares | — | 0.36 Cr | 0.36 Cr | 0.36 Cr | 0.36 Cr |
| Basic Average Shares | — | 0.36 Cr | 0.36 Cr | 0.36 Cr | 0.36 Cr |
| Diluted EPS | — | 44.19 | 18.04 | 25.32 | 37.94 |
| Basic EPS | — | 44.19 | 18.04 | 25.32 | 37.94 |
| Other Special Charges | — | 0.16 Cr | -0.04 Cr | -0.96 Cr | -0.02 Cr |
| Interest Income Non Operating | — | 3.36 Cr | 1.79 Cr | 1.75 Cr | 2.04 Cr |
| Amortization | — | 34000.00 | 84000.00 | 0.01 Cr | 0.02 Cr |
| Selling General And Administration | — | 6.19 Cr | 3.11 Cr | 4.70 Cr | 8.26 Cr |
| Selling And Marketing Expense | — | 2.16 Cr | 1.36 Cr | 2.14 Cr | 4.65 Cr |
| General And Administrative Expense | — | 4.02 Cr | 1.74 Cr | 2.56 Cr | 3.61 Cr |
| Rent And Landing Fees | — | 1.74 Cr | 2.41 Cr | 0.55 Cr | 0.38 Cr |
| Total Other Finance Cost | — | — | — | — | 0.24 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Coral Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.